Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBOREIN: CK2 and ATM Inhibitors in Renal Tumor Cultures
NCT03571438Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- Oct 2017
- Primary completion
- Sep 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of silmitasertib and KU-60019 in clear cell renal cell carcinoma (ccRCC) (4 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Incidence of cell death on organotypic cultures of human renal tumors. Status: unknown.
02
Drugs
silmitasertibKU-60019
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03571438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571438.